Why the study?
Dyslipidemia is a major risk for the development and progression of atherosclerotic cardiovascular disease, and effective therapies are available to improve lipid profiles and reduce cardiovascular events.
Provides comprehensive clinical practice guidelines from the AACE/ACE for diagnosing and managing dyslipidemia to reduce cardiovascular events.
Guides clinicians in optimizing dyslipidemia care to lower CV risk; extends prior AACE/ACE recommendations with updated targets and strategies.
The American Association of Clinical Endocrinology and the American College of Endocrinology Clinical Practice Guideline is a comprehensive, practical tool that can be used to diagnose and manage dyslipidemia, a major risk for the development and progression of atherosclerotic cardiovascular disease. Effective therapies are available to improve lipid profiles and reduce cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Ciffone et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: